Abstract: The invention provides and describes solid state 17?-ethynyl-androst-5-ene-3?,7?,17?-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17?-ethynyl-androst-5-ene-3?,7?,17?-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17?-ethynyl-androst-5-ene-3?,7?,17?-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17?-ethynyl-androst-5-ene-3?,7?,17?-triol and uses of such formulations in treating the described conditions.

Abstract: Crystalline forms of 5-(4-cyclopropyl-1H-imidazol-1-yl)-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-2-fluoro-4-methylbenzamide(Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the crystalline forms.

Abstract: The invention provides and describes solid state 17?-ethynyl-androst-5-ene-3?,7?,17?-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17?-ethynyl-androst-5-ene-3?,7?,17?-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17?-ethynyl-androst-5-ene-3?,7?,17?-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17?-ethynyl-androst-5-ene-3?,7?,17?-triol and uses of such formulations in treating the described conditions.

Abstract: A box-shaped electric control cabinet is provided which can be closed by a cover and which is used to receive electric components and devices for a blade angle adjustment drive (pitch drive) of a wind energy power plant, by means of which one or more rotor blades of the plant can be rotated about the blade axis. The control cabinet includes at least two cabinet segments, and specific electric components and devices are associated with respectively each module according to its function. The cabinet segments can be associated with and/or assigned to respectively different electric components and devices, with which, combined as a part function, different total functions and/or embodiment forms of the control cabinet can be produced or are producible.

Abstract: Crystalline forms of 5-(4-cyclopropyl-1H-imidazol-1-yl)-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-2-fluoro-4-methylbenzamide (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the crystalline forms.

Abstract: The invention provides and describes solid state 17?-ethynyl-androst-5-ene-3?,7?,17?-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17?-ethynyl-androst-5-ene-3?,7?,17?-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17?-ethynyl-androst-5-ene-3?,7?,17?-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17?-ethynyl-androst-5-ene-3?,7?,17?-triol and uses of such formulations in treating the described conditions.

Abstract: The invention provides and describes solid state 17?-ethynyl-androst-5-ene-3?,7?,17?-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17?-ethynyl-androst-5-ene-3?,7?,17?-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17?-ethynyl-androst-5-ene-3?,7?,17?-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17?-ethynyl-androst-5-ene-3?,7?,17?-triol and uses of such formulations in treating the described conditions.

Abstract: The invention provides and describes solid state 17?-ethynyl-androst-5-ene-3?,7?,17?-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17?-ethynyl-androst-5-ene-3?,7?,17?-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17?-ethynyl-androst-5-ene-3?,7?,17?-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17?-ethynyl-androst-5-ene-3?,7?,17?-triol and uses of such formulations in treating the described conditions.

Abstract: A method for the isolation of specific molecules which bind highly selectively to chosen target molecules. In particular, due to displacement with a specific competitor, binding molecules are selected which preferably bind to previously known epitopes.

Abstract: Crystalline salts of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine, compositions thereof, methods for their preparation, and methods for their use are disclosed.

Abstract: A method for the hydrometallurgical recovery of lithium from the fraction of used galvanic cells containing lithium, iron and phosphate.

Abstract: The invention relates to a method for the hydrometallurgical recovery of lithium from the lithium manganese oxide-containing fraction of used galvanic cells.

Abstract: A method for the hydrometallurgical recovery of lithium from a lithium transition metal oxide-containing fraction of used galvanic cells.

Abstract: Crystalline salts of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine, compositions thereof, methods for their preparation, and methods for their use are disclosed.

Abstract: Crystalline salts of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine, compositions thereof, methods for their preparation, and methods for their use are disclosed.

Abstract: An improved electrical disconnect apparatus includes a set of spaced apart conductors and a removable conductive element that is structured to extend between the conductors and to complete at least a portion of an electrical circuit that includes the conductors. The electrical disconnect apparatus is situated between an electrical network and a network protector. The conductors and the conductive element which extends therebetween are situated within the interior of a support that is sealed in order to permit the electrical disconnect apparatus to be in a submerged environment during use. The conductive element is retained by a key interlock wherein the key that enables removal of the conductive element is stored on the network protector and is only made available to the technician when the network protector has been switched to an OFF condition.

Abstract: An electrical disconnect apparatus includes a housing having a first conductor configured to electrically connect to a first external circuit and a second conductor configured to electrically connect to a second external circuit; and a connection device having an elongated portion structured to be inserted into and removed from the housing. The elongated portion of the connection device includes a fuse having a first conductive end portion and a second conductive end portion electrically connected by a fusible element. The fuse electrically connects the first conductor to the second conductor when the elongated portion of the connection device is inserted into the housing and electrically disconnects the first conductor from the second conductor when the elongated portion of the connection device is removed from the housing.

Abstract: Crystalline salts of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine, compositions thereof, methods for their preparation, and methods for their use are disclosed.

Abstract: A steam turbine having an exhaust-steam casing for directing an exhaust-steam mass flow, a shaft bearing for mounting a turbine shaft, and at least two bearing struts, by means of which the shaft bearing is fastened to the exhaust-steam casing, is characterized according to the invention in that each of the at least two bearing struts has a cooling cavity arranged in the respective bearing strut for directing a coolant, and the cooling cavities of the at least two bearing struts are connected in a fluidically conductive manner via a closed-off connecting cavity in the region of the shaft bearing.

Abstract: An improved electrical disconnect apparatus includes a set of spaced apart conductors and a removable conductive element that is structured to extend between the conductors and to complete at least a portion of an electrical circuit that includes the conductors. The electrical disconnect apparatus is situated between an electrical network and a network protector. The conductors and the conductive element which extends therebetween are situated within the interior of a support that is sealed in order to permit the electrical disconnect apparatus to be in a submerged environment during use. The conductive element is retained by a key interlock wherein the key that enables removal of the conductive element is stored on the network protector and is only made available to the technician when the network protector has been switched to an OFF condition.